Vitamin B3-related NAD+ precursor · Fact sheet
Nicotinamide riboside
Also known as NR · niagen
Nicotinamide riboside can raise NAD-related biomarkers in people, but it is not an FDA-approved drug for aging, cognitive decline, mitochondrial disease, or fatigue. Biomarker movement should not be confused with proven health benefit.
What is Nicotinamide riboside?
Nicotinamide riboside is a vitamin B3-related compound and one of several precursors cells can use to make NAD+.
It is sold in dietary supplements, a category FDA does not approve for safety and effectiveness before marketing.
Benefits people look for
NR offers an oral way to influence NAD metabolism without administering NAD+ itself.
It is studied across metabolic, cardiovascular, muscle, neurological, and aging-related questions, but small trials and multiple endpoints make isolated positive signals easy to overinterpret.
What the evidence supports
- Trials commonly report increased blood NAD-related metabolites.
- A randomized pilot in mild cognitive impairment found target engagement but did not show a significant cognitive benefit over placebo.
All research areas
- NAD+ metabolism
- Mild cognitive impairment
- Cardiometabolic and vascular outcomes
- Muscle and mitochondrial function
Anecdotal reports & lived experiences
Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens.
No attributable personal reports are summarized here yet. The benefits above describe research interests; the side effects below come from the cited medical sources.
We do not fill this gap with unsourced testimonials or estimated success rates.
Side effects & risks
- Short controlled studies generally report acceptable tolerability, but they are not large or long enough to define uncommon harms.
- Supplement strength, purity, and labeling can vary, and FDA does not preapprove supplements for effectiveness.
- Long-term consequences of chronically altering NAD metabolism in diverse populations are uncertain.
This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.
Clinical research: how strong is it?
Early human evidenceMultiple human trials establish absorption and biomarker effects. Controlled studies have not yet established a durable, reproducible benefit on cognition, physical function, or major clinical outcomes.
Selected research to read
Placebo-controlled pilot reporting biomarker engagement without a significant cognitive benefit.
Review of human NR and NMN trials describing consistent biomarker effects and heterogeneous clinical outcomes.
What do the human studies show?
Selected research questions, not a complete inventory of indications or trials. Source checking is not independent clinical review. How we read the evidence.
| Study and people | Question and follow-up | Result and limits |
|---|---|---|
| NR mild cognitive impairment pilot Older adults with mild cognitive impairment 20 participants (actual) Randomized placebo-controlled trial; human | Nicotinamide riboside versus Placebo 10 weeks Primary: Change in Montreal Cognitive Assessment score DNA methylation; secondary blood NAD+ and other functional measures. Phase: Not listed in this summary | Blood NAD+ increased; cognition did not change. Cannot tell us: Too small and short to establish prevention of dementia or rare harms. Cerebral blood-flow findings did not survive correction for multiple comparisons. Safety, uncertainty, and source detailsNo between-group difference in reported adverse events in this small pilot. Limited to the studied population, formulation and follow-up. Funding/conflicts: Not confirmed in this summary; check the full paper. Source checked: 2026-09-18. Independent clinical review: not completed. |
What these results can and cannot tell us
Did higher blood NAD+ improve cognition in the NR pilot?
Biomarker change occurred without a demonstrated cognitive improvement in this pilot.
Limit: A biomarker increase does not itself establish patient benefit or dementia prevention.
Check the sources: Nicotinamide riboside pilot in mild cognitive impairment (checked 2026-09-18)
Related, not equivalent: NAD+ · Nicotinamide mononucleotide.
Compare research questions · Submit a source-based correction
FDA approval & research status
No nicotinamide-riboside drug is FDA approved to prevent or treat aging, cognitive decline, mitochondrial dysfunction, or fatigue. Dietary-supplement marketing does not equal FDA approval.
No FDA-approved use is documented in the records summarized on this page.
Supplement and food-ingredient status, not drug approval
Nicotinamide riboside has human biomarker trials and food-ingredient regulatory material, but no FDA-approved drug use for aging, cognition, fatigue, or disease treatment.
This summarizes the cited product or research record. Trial phases do not establish successful completion of earlier stages, and a stopped program is not ongoing development. Approval applies only to the labeled product, use and population.
What we still don’t know
- Whether any biomarker change improves healthspan or disease outcomes
- Whether a specific deficient or disease-defined population benefits
- Long-term safety and clinically meaningful interactions
- How NR compares with NMN or lifestyle interventions on patient-centered outcomes
The takeaway
NR has credible human target-engagement data, but a higher NAD biomarker is a research result—not proof of better memory, energy, or longevity.
Sources & further reading
Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.
- 1pubmedRandomized NR pilot in mild cognitive impairment
Placebo-controlled pilot reporting biomarker engagement without a significant cognitive benefit.
- 2pubmedSystematic review of NAD precursor trials
Review of human NR and NMN trials describing consistent biomarker effects and heterogeneous clinical outcomes.
- 3fdaFDA GRAS notice response materials for NR chloride
Food-ingredient regulatory record; GRAS status is not approval of anti-aging or disease claims.
- 4fdaFDA: what ‘FDA approved’ does and does not mean
FDA explains that dietary supplements are not approved for safety and effectiveness before marketing.